Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics ( ARQT ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Are Medical Stocks Lagging Arcutis Biotherapeutics ( ARQT ) This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Tenet Healthcare (THC) have performed compared to their sector so far this year.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Arcutis Biotherapeutics ( NASDAQ:ARQT )
WESTLAKE VILLAGE, Calif., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ARQT, a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 21,000 restricted stock units of Arcutis' ...
Arcutis ( ARQT ) Q2 Revenue Soars 164%
Arcutis Biotherapeutics ( NASDAQ:ARQT ) , a dermatology-focused pharmaceutical company, reported earnings results on August 6, 2025. Highlights included strong revenue growth and improved earnings, significantly outperforming Wall Street expectations, with GAAP revenue of $81.5 million and GAAP ...
Arcutis Biotherapeutics, Inc. ( ARQT ) Reports Q2 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Arcutis Biotherapeutics, Inc. ( ARQT ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Applied Optoelectronics ( NASDAQ:AAOI ) , Arcutis Biotherapeutics ( NASDAQ:ARQT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Ryan Koontz initiated coverage on Applied Optoelectronics, Inc.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
WESTLAKE VILLAGE, Calif., July 03, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ( Nasdaq: ARQT ) , a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 14,000 restricted stock ...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Arcutis Biotherapeutics ( NASDAQ:ARQT )
WESTLAKE VILLAGE, Calif., June 06, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ARQT, a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 72,000 restricted stock units of Arcutis' ...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
WESTLAKE VILLAGE, Calif., June 06, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ( Nasdaq: ARQT ) , a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 72,000 restricted stock ...
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis - Arcutis Biotherapeutics ( NASDAQ:ARQT )
Zoryve cream helped 63.1% of children aged 2-5 reach vIGA-AD 0/1 after 56 weeks. Only 2.5% of kids aged 2-5 experienced treatment-related side effects in the study. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here. Arcutis Biotherapeutics, Inc.
Arcutis' ZORYVE® ( roflumilast ) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - Arcutis Biotherapeutics ( NASDAQ:ARQT )
Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of use More than half of the nearly 9 million people in the United States with plaque psoriasis experience scalp involvement
Arcutis' ZORYVE® ( roflumilast ) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
FDA has approved the supplemental New Drug Application (sNDA) for ZORYVE® foam 0.3% for the treatment of plaque psoriasis ...
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice - Arcutis Biotherapeutics ( NASDAQ:ARQT )
Arcutis convened the Genital Psoriasis Wellness Consortium, a multidisciplinary group of clinicians who are experts in their fields Publication includes 14 consensus statements aimed at improving diagnosis, treatment, outcomes, and shared decision-making
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
Arcutis announced the publication of 14 consensus statements from the Genital Psoriasis Wellness Consortium on the impact of genital psoriasis on patients.
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® ( roflumilast ) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
JAMA Dermatology published the positive results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE® (roflumilast) foam ...
Arcutis Biotherapeutics, Inc. ( ARQT ) Reports Q1 Loss, Tops Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of 4.76% and 3.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Phathom Pharmaceuticals, Inc. ( PHAT ) Reports Q1 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -0.94% and 1.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Qiagen ( QGEN ) Reports Next Week: Wall Street Expects Earnings Growth
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcutis Biotherapeutics, Inc. ( ARQT ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Arcutis Biotherapeutics ( ARQT ) Stock Outpacing Its Medical Peers This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Arcutis Announces Chief Financial Officer Transition - Arcutis Biotherapeutics ( NASDAQ:ARQT )
WESTLAKE VILLAGE, Calif., April 10, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
WESTLAKE VILLAGE, Calif., April 04, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ( Nasdaq: ARQT ) , a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 35,000 restricted stock ...
Arcutis Biotherapeutics ( ARQT ) Moves 10.8% Higher: Will This Strength Last?
Arcutis Biotherapeutics (ARQT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arcutis and Padagis Agree to Stay Patent Lawsuit - Arcutis Biotherapeutics ( NASDAQ:ARQT )
WESTLAKE VILLAGE, Calif., April 02, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc.
Arcutis and Padagis Agree to Stay Patent Lawsuit
WESTLAKE VILLAGE, Calif., April 02, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ( Nasdaq: ARQT ) , a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, is pleased to announce that Padagis Israel Pharmaceuticals Ltd., ...
How Much Upside is Left in Arcutis Biotherapeutics ( ARQT ) ? Wall Street Analysts Think 25.85%
The consensus price target hints at a 25.9% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are Medical Stocks Lagging Cardinal Health ( CAH ) This Year?
Here is how Cardinal Health (CAH) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Tonix Pharmaceuticals ( NASDAQ:TNXP ) , Arcutis Biotherapeutics ( NASDAQ:ARQT )
As of March 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...
Has Arcutis Biotherapeutics ( ARQT ) Outpaced Other Medical Stocks This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
Arcutis today announced new data from two posters shared at the 2025 American Academy of Dermatology Annual Meeting (AAD).
Arcutis Biotherapeutics, Inc. ( ARQT ) Just Overtook the 50-Day Moving Average
When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics ( ARQT ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 48.4% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
Arcutis today announced that it will present two posters at the 2025 AAD annual meeting which will take place in Orlando, FL, from March 7-11, 2025.
Arcutis Biotherapeutics, Inc. ( ARQT ) Reports Q4 Loss, Tops Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of 66.67% and 23.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Arcutis Biotherapeutics ( NASDAQ:ARQT )
WESTLAKE VILLAGE, Calif., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Q4 2024 net product revenue for ZORYVE® ( roflumilast ) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024.
Intellia Therapeutics, Inc. ( NTLA ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference - Arcutis Biotherapeutics ( NASDAQ:ARQT )
WESTLAKE VILLAGE, Calif., Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ARQT, a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 45th Annual ...
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference
WESTLAKE VILLAGE, Calif., Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ( Nasdaq: ARQT ) , a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen ...
Wall Street Analysts Think Arcutis Biotherapeutics ( ARQT ) Could Surge 51.64%: Read This Before Placing a Bet
The consensus price target hints at a 51.6% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ultragenyx ( RARE ) Reports Q4 Loss, Tops Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -12.10% and 1.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcutis Biotherapeutics ( ARQT ) Surges 15.9%: Is This an Indication of Further Gains?
Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Here's Why Arcutis Biotherapeutics ( ARQT ) Could be Great Choice for a Bottom Fisher
Arcutis Biotherapeutics (ARQT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's ...
Incyte ( INCY ) Q4 Earnings Miss Estimates
Incyte (INCY) delivered earnings and revenue surprises of -6.54% and 2.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Arcutis Biotherapeutics ( NASDAQ:ARQT )
WESTLAKE VILLAGE, Calif., Feb. 05, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ARQT, a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 62,000 restricted stock units of Arcutis' ...
CRL Gears Up for Q4 Earnings: Here's What You Need to Know
Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.
STE Gears Up for Q3 Earnings: Here's What You Need to Know
STERIS' third-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog and increasing bioprocessing demand.
ALGN Gears Up for Q4 Earnings: What Lies Ahead for the Stock?
Align Technology's fourth-quarter results are likely to reflect the strength in its Systems & Services business.
Are Medical Stocks Lagging Addus HomeCare ( ADUS ) This Year?
Here is how Addus HomeCare (ADUS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
IDXX Gears Up for Q4 Earnings: What to Expect From the Stock?
IDEXX Laboratories' fourth-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.
